Possible Legislation Regarding ESA Administration On The Horizon
This article was originally published in The Pink Sheet Daily
OIG report on administration protocols for erythropoiesis-stimulating agents at dialysis facilities for renal disease patients could lay foundation for possible legislation or CMS administrative action, a staffer for Rep. Stark says.
You may also be interested in...
In anticipation of objections to its proposal to include oral end-stage renal disease drugs currently covered under Medicare Part D in bundled payments for ESRD services, CMS offered an extensive justification for the action
Congress will start looking at the specifics of how to bundle payment for a variety of services related to end-stage renal disease treatment, now that CMS has issued a report on the subject
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.